ABSTRACT
Objective
To compare hemithyroidectomy eligibility and completion thyroidectomy recommendations under the ATA 2015 and ATA 2025 criteria within the same patient cohort (primary aim) and, as a secondary descriptive analysis, to assess the concordance between these guideline‐based classifications and the operations actually performed.
Methods
Retrospective cohort study of adult patients who underwent primary hemithyroidectomy for differentiated thyroid carcinoma at a tertiary center (January 2015–November 2025). NIFTP and tumors of uncertain malignant potential were excluded from the comparative analysis. Each case was independently reclassified by ATA 2015 and ATA 2025 criteria using final histopathology (a retrospective, hindsight reclassification that could not have informed preoperative decisions); paired comparisons used the McNemar test.
Results
Of 98 patients, 86 were eligible for comparative analysis. Hemithyroidectomy eligibility increased from 60.5% (52/86) under ATA 2015 to 81.4% (70/86) under ATA 2025 (absolute increase 20.9 points; 95% CI 12.3–29.5; p < 0.001). Completion thyroidectomy indications decreased from 44.2% (38/86) to 29.1% (25/86) (absolute reduction 15.1 points; 95% CI 7.5–22.7; p < 0.001). Despite this reduction, completion was actually performed in 40.7% (35/86) of the comparative cohort (vs. 35.7% overall; the difference reflects exclusion of NIFTP and tumors of uncertain malignant potential).
Conclusion
The ATA 2025 criteria substantially expand hemithyroidectomy eligibility and reduce completion thyroidectomy indications compared with ATA 2015. Real‐world completion rates nonetheless exceeded guideline‐based projections, suggesting that additional pathological and clinical factors may influence individualized surgical decision‐making. These findings characterize the guideline update's impact on surgical strategy and do not address long‐term oncologic outcomes, which were beyond this study's scope.
Level of Evidence
4.
Keywords: completion thyroidectomy, differentiated thyroid cancer, guideline implementation, hemithyroidectomy, real‐world practice, risk stratification, treatment de‐escalation
1. Introduction
Over the past decade, evolving clinical guidelines have reshaped the surgical management of differentiated thyroid cancer (DTC), particularly in patients with low‐risk disease. The American Thyroid Association (ATA) 2015 guidelines recommended hemithyroidectomy (HT) as an acceptable alternative to total thyroidectomy (TT) in selected low‐risk DTC cases, with the aim of minimizing unnecessary surgical morbidity. The 2025 ATA update further consolidated this de‐escalation paradigm by refining risk classification, emphasizing individualized decision‐making, and expanding eligibility for HT while reducing the need for completion thyroidectomy (CT) [1, 2, 3]. However, the extent to which these updated recommendations are reflected in real‐world practice and how they influence surgical decision‐making remains incompletely understood.
Much of the rising incidence of thyroid cancer is attributed to the more frequent detection of small, low‐risk papillary thyroid carcinomas (PTC), raising concerns about overtreatment. Autopsy studies have demonstrated that histopathological features traditionally considered “high risk” are frequently observed in clinically occult thyroid cancers; however, these findings do not consistently translate into adverse clinical outcomes [4, 5]. These observations support the premise that limited surgical approaches may be oncologically safe in appropriately selected patients.
The 2015 ATA guidelines established HT as an appropriate surgical option, particularly for patients with 1–4 cm, intrathyroidal, unifocal PTC without clinically apparent lymph node metastasis [1, 6]. The principal rationale for this approach is the recognized lower surgical morbidity of hemithyroidectomy relative to total thyroidectomy, including a reduced risk of permanent hypoparathyroidism and recurrent laryngeal nerve injury [7, 8, 9].
De‐escalation strategies extend beyond the scope of surgical intervention. Reduced use of radioactive iodine (RAI) in low‐risk patients has become another cornerstone of guideline‐directed management, without evidence of increased recurrence in appropriately selected cases [3, 8]. In parallel, active surveillance has gained increasing acceptance as a viable alternative to immediate surgery in carefully selected patients, particularly in very low‐risk PTC [4, 10].
Despite these advances, completion thyroidectomy may still be required when unexpected adverse pathological features are identified following HT. However, some features historically labeled as “high risk” may have limited clinical significance and do not necessarily warrant surgical escalation [5]. By incorporating molecular data and refined risk stratification into individualized surgical decision‐making, the 2025 ATA guidelines further reinforce a patient‐centered framework [2].
In this context, determining whether the ATA 2025 revision meaningfully expands hemithyroidectomy eligibility and reduces indications for completion thyroidectomy compared with the 2015 version represents a clinically relevant and timely research question. Moreover, evaluating the concordance between guideline‐based recommendations and real‐world surgical practice is essential for understanding the practical impact of de‐escalation strategies [1, 3].
Therefore, the primary objective of this retrospective cohort study was to compare hemithyroidectomy eligibility and completion thyroidectomy recommendations under the ATA 2015 and ATA 2025 criteria within the same patient cohort. As a secondary, descriptive objective, we examined the concordance between these guideline‐based classifications and the operations actually performed.
2. Materials and Methods
This retrospective, single‐center observational cohort study included adult patients who underwent primary hemithyroidectomy at the Department of General Surgery, School of Medicine, Marmara University between January 2015 and November 2025. The study was approved by the Marmara University School of Medicine Clinical Research Ethics Committee (Approval No: 09.2025.25.1080) and conducted in accordance with the principles of the Declaration of Helsinki.
Patients were included if they had a confirmed postoperative diagnosis of differentiated thyroid carcinoma. Those with benign pathology, those who underwent primary TT for bilateral disease, those with incomplete clinical or pathological data, and those who had undergone reoperation for recurrence were excluded. Tumors were classified according to the WHO Classification of Thyroid Neoplasms (2022, 5th edition) [11]. Non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) and follicular tumors of uncertain malignant potential were excluded from analyses evaluating surgical eligibility and completion thyroidectomy recommendations according to ATA guidelines [3].
Demographic, clinical, and pathological data were obtained from the hospital information management system and archived medical records. Demographic variables included age, sex, American Society of Anesthesiologists (ASA) physical status score, and the Charlson Comorbidity Index (CCI). The CCI was retrospectively calculated from patient records according to standard scoring methodology and categorized into two groups (0 vs. ≥ 1) for analysis [12].
Surgical decision‐making during the study period was primarily guided by the ATA 2015 guidelines; however, treatment strategies were also influenced by institutional practice patterns, surgeon experience, and patient‐specific clinical factors [6]. Surgical variables included the date of surgery, surgeon's annual thyroidectomy volume, operative duration, tumor laterality, and margin status.
Marmara University Hospital is a high‐volume tertiary referral center for endocrine surgery, where the majority of procedures were performed by experienced endocrine surgeons [13]. Intraoperative nerve monitoring was employed in the majority of cases. Surgeon volume was classified according to the criteria referenced in the 2025 ATA guidelines, and surgeons performing ≥ 25 thyroidectomies per year were considered high‐volume [3].
Surgical margin status was determined from the pathology reports. A margin was considered positive when tumor cells were present at the inked surgical margin, whereas a close margin was defined as a tumor‐to‐margin distance of ≤ 1 mm without ink involvement. For descriptive purposes, close and positive margins were combined into a single category in Table 1. The ≤ 1 mm threshold for a close margin was an institution‐specific definition used solely for descriptive categorization and was not an ATA guideline‐defined indication for completion thyroidectomy. In the guideline‐based reclassification, only a true positive margin, defined as tumor at the inked margin (R1), was considered a completion‐relevant finding. Close margins are not classified as R1 resections under ATA definitions [3, 6, 14].
TABLE 1.
Clinical and demographic characteristics of the study population (N = 98).
| Variable | N = 98 |
|---|---|
| Age (years), mean ± SD | 45.1 ± 13.5 |
| Sex, n (%) | |
| Female | 78 (79.6) |
| Male | 20 (20.4) |
| ASA score, n (%) | |
| I | 58 (59.2) |
| II | 36 (36.7) |
| III | 4 (4.1) |
| Charlson Comorbidity Index, n (%) | |
| 0 | 39 (39.8) |
| ≥ 1 | 59 (60.2) |
| Surgeon volume, n (%) | |
| High‐volume (≥ 25/year) | 87 (88.8) |
| Low‐volume (< 25/year) | 11 (11.2) |
| Operative time (min), median (IQR) | 77.5 (30) |
| Tumor laterality, n (%) | |
| Right | 59 (60.2) |
| Left | 39 (39.8) |
| Surgical margin status, n (%) | |
| Negative | 85 (86.7) |
| Close/positive a | 13 (13.3) |
Abbreviations: ASA, American Society of Anesthesiologists physical status; IQR, interquartile range; SD, standard deviation.
Close/positive margin defined as tumor–margin distance ≤ 1 mm or tumor cells present at the inked surgical margin.
Pathological assessment included tumor subtype, tumor size and size categories, capsule invasion, lymphovascular invasion, multifocality, macroscopic extrathyroidal extension, and incidental central lymph node metastasis. Clinical outcome variables included completion thyroidectomy and follow‐up duration.
Each patient was retrospectively reclassified according to the 2015 and 2025 ATA guideline criteria using available clinical and pathological data [3, 6]. This classification represents a post hoc assessment based on final histopathological findings and was used to evaluate the concordance between guideline‐based recommendations and the extent of surgery in hindsight, rather than to reflect preoperative decision‐making.
For analytical purposes, hemithyroidectomy eligibility and completion thyroidectomy recommendations were categorized as “appropriate/inappropriate” and “recommended/not recommended,” respectively. Reclassification was based on guideline‐defined pathological parameters available postoperatively, including tumor size, extrathyroidal extension and its extent, surgical margin status, multifocality, lymphovascular invasion, central lymph node involvement, aggressive histological subtype, and capsular invasion, interpreted within each guideline's risk‐of‐recurrence framework. This was a retrospective, hypothetical reclassification; the actual surgical decisions were not informed by the ATA 2025 guidelines, and the agreement between guideline‐based recommendations and observed practice is therefore reported as descriptive concordance rather than as a measure of guideline adherence. Two reviewers independently categorized each case in separate fields within a shared spreadsheet; discordant classifications were discussed and resolved by consensus. Because a single consensus classification was retained rather than each reviewer's independent ratings, a formal inter‐rater agreement statistic (Cohen's κ) could not be calculated. The reviewers were not blinded to whether completion thyroidectomy had actually been performed, as this information was contained in the same records used for reclassification; the resulting potential for bias is addressed in the Limitations.
2.1. Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics for Mac, Version 24. Continuous variables were presented as mean ± standard deviation or median (interquartile range), based on data distribution. Categorical variables were expressed as numbers and percentages. The McNemar test was used to compare matched categorical variables, specifically surgical eligibility and completion thyroidectomy recommendations according to the ATA 2015 and ATA 2025 guidelines for the same patients. Agreement between actual completion thyroidectomy and guideline‐based recommendations was evaluated using descriptive cross‐tabulation and odds ratio (OR) analysis. A p value < 0.05 was considered statistically significant. The 95% confidence intervals (CI) for the difference between paired proportions were calculated using the Newcombe method to assess the magnitude of change between the 2015 and 2025 ATA guidelines. As the two paired comparisons were prespecified and non‐redundant, no formal correction for multiple comparisons was applied, and the reported p values and confidence intervals should be interpreted accordingly.
3. Results
3.1. Patient Characteristics
A total of 98 patients who underwent primary hemithyroidectomy during the study period and were diagnosed with differentiated thyroid carcinoma based on postoperative histopathological examination were included. The mean age was 45.1 ± 13.5 years, and 79.6% of patients were female. The majority of patients were classified as ASA I–II (95.9%). The Charlson Comorbidity Index was 0 in 39 patients (39.8%) and ≥ 1 in 59 patients (60.2%).
Using the predefined high‐volume threshold (≥ 25 thyroidectomies per year), 88.8% of procedures were performed by high‐volume surgeons and 11.2% by lower‐volume surgeons. The median operative time was 77.5 min (IQR: 30). Surgical margins were negative in 86.7% of cases and classified as close/positive in 13.3% (Table 1).
3.2. Pathological Findings
The most frequent postoperative diagnosis was PTC, accounting for 63.3% of cases, followed by follicular thyroid carcinoma (11.2%). NIFTP and follicular tumors of uncertain malignant potential together comprised 12.2% of cases and were excluded from guideline‐based eligibility analyses.
Among the PTC subtypes, the most frequent were the classical type (40.3%) and the infiltrative follicular variant (30.6%). Aggressive variants, including tall cell, hobnail, and diffuse sclerosing subtypes, were identified in a minority of cases (Table 2).
TABLE 2.
Histopathological outcomes and postoperative clinical status following hemithyroidectomy.
| Variable | N = 98 |
|---|---|
| Postoperative diagnosis, n (%) | |
| Papillary thyroid carcinoma (PTC) | 62 (63.3) |
| PTC subtype, n (%) a | |
| Classical | 25 (40.3) |
| Infiltrative follicular variant | 19 (30.6) |
| Oncocytic | 6 (9.7) |
| Encapsulated classical | 1 (1.6) |
| Tall cell | 4 (6.5) |
| Hobnail | 1 (1.6) |
| Diffuse sclerosing | 2 (3.2) |
| Solid/trabecular | 3 (4.8) |
| Warthin‐like | 1 (1.6) |
| Follicular thyroid carcinoma | 11 (11.2) |
| NIFTP b | 10 (10.2) |
| Invasive encapsulated follicular variant PTC | 10 (10.2) |
| Oncocytic carcinoma | 3 (3.1) |
| Follicular tumor of uncertain malignant potential | 2 (2.0) |
| Tumor size (mm), median (IQR) | 12.5 (8–25) |
| Tumor size category, n (%) | |
| ≤ 1 cm | 40 (40.8) |
| > 1 to ≤ 2 cm | 29 (29.6) |
| > 2 to ≤ 4 cm | 29 (29.6) |
| Capsular invasion, n (%) | 45 (45.9) |
| Lymphovascular invasion, n (%) | 21 (21.4) |
| Multifocality, n (%) | 31 (31.6) |
| Macroscopic extrathyroidal extension, n (%) | 7 (7.1) |
| Incidental central lymph node metastasis, n (%) | |
| Present | 9 (9.2) |
| Absent | 89 (90.8) |
| Completion thyroidectomy performed, n (%) c | 35 (35.7) |
| Follow‐up duration (months), median (IQR) | 5 (2–14) |
Note: Tumors were classified according to the WHO Classification of Thyroid Neoplasms (2022, 5th edition).
Abbreviation: IQR, interquartile range.
PTC subtype percentages calculated among patients with papillary thyroid carcinoma (n = 62).
NIFTP: non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features.
Completion thyroidectomy rate reflects the overall cohort (N = 98).
Seven tumors had aggressive histological subtypes (four tall cell, one hobnail, two diffuse sclerosing); under ATA 2025, five of these were classified as having a completion indication. In a sensitivity analysis excluding these cases, hemithyroidectomy eligibility under ATA 2025 was 84.8% and the proportion with a completion indication was 25.3%, leaving the principal findings unchanged.
The median tumor size was 12.5 mm (IQR: 8–25). The tumor size distribution was ≤ 1 cm in 40.8%, > 1 to ≤ 2 cm in 29.6%, and > 2 to ≤ 4 cm in 29.6%. Capsular invasion was present in 45.9%, lymphovascular invasion in 21.4%, and multifocality in 31.6% of the patients. Macroscopic extrathyroidal extension was observed in 7.1% of patients. Incidental central lymph node metastasis was detected in 9.2% of patients (Table 2).
Completion thyroidectomy was performed in 35 (35.7%) of 98 patients in the overall cohort. The median follow‐up duration was 5 months (IQR: 2–14 months).
3.3. Reclassification According to the ATA Guidelines
After excluding NIFTP and tumors of uncertain malignant potential, 86 patients were included in the comparative guideline‐based analysis (Table 3). According to the ATA 2015 criteria, hemithyroidectomy was considered appropriate in 52 (60.5%) and inappropriate in 34 (39.5%) patients.
TABLE 3.
Comparative analysis of ATA 2015 and ATA 2025 surgical recommendations and their concordance with real‐world practice (N = 86; NIFTP and tumors of uncertain malignant potential excluded).
| ATA 2015 | ATA 2025 | p a | Absolute difference (95% CI) | |
|---|---|---|---|---|
| A. Guideline‐concordant hemithyroidectomy eligibility b | ||||
| Appropriate, n (%) | 52 (60.5) | 70 (81.4) | < 0.001 | 20.9% (12.3%–29.5%) |
| Inappropriate, n (%) | 34 (39.5) | 16 (18.6) | — | — |
| B. Recommendation for completion thyroidectomy | ||||
| Recommended, n (%) | 38 (44.2) | 25 (29.1) | < 0.001 | 15.1% (7.5%–22.7%) |
| Not recommended, n (%) | 48 (55.8) | 61 (70.9) | — | — |
| C. Actual completion thyroidectomy performed | ||||
| n (%) | ||||
| Completion thyroidectomy performed | 35 (40.7) | |||
| No completion thyroidectomy | 51 (59.3) | |||
| D. Concordance between guideline recommendation and real‐world practice | ||||
| ATA 2015 | ATA 2025 | |||
| OR (95% CI) | 3.00 (1.23–7.32) | 5.08 (1.86–13.86) | ||
Note: Bold values indicate statistical significance (p < 0.05).
Abbreviations: CI, confidence interval; OR, odds ratio.
McNemar test for paired categorical comparisons between ATA 2015 and ATA 2025 criteria.
Eligibility classifications represent a retrospective, post hoc assessment based on final histopathological findings and do not reflect preoperative decision‐making.
Under the ATA 2025 criteria, eligibility for hemithyroidectomy increased to 70 patients (81.4%), while only 16 patients (18.6%) were classified as inappropriate—an absolute increase of 20.9 percentage points (95% CI: 12.3%–29.5%; McNemar test, p < 0.001).
Regarding completion thyroidectomy recommendations, ATA 2015 would have recommended completion surgery in 38 patients (44.2%), whereas this proportion decreased to 25 patients (29.1%) under ATA 2025—an absolute reduction of 15.1 percentage points (95% CI: 7.5%–22.7%; McNemar test, p < 0.001).
The association between guideline‐recommended indications and clinical practice was stronger under ATA 2025 (OR: 5.08, 95% CI: 1.86–13.86) than under ATA 2015 (OR: 3.00, 95% CI: 1.23–7.32).
3.4. Concordance Between Guideline Recommendations and Clinical Practice
In actual practice, 35 of the 86 analyzed patients (40.7%) underwent completion thyroidectomy; this rate differs from the rate in the overall cohort (35.7%) due to the exclusion of NIFTP and tumors of uncertain malignant potential from the comparative analysis.
According to the 2015 ATA recommendations, 21 of the 38 patients for whom completion thyroidectomy was recommended underwent surgery, while 17 did not. Additionally, 14 of the 48 patients for whom completion thyroidectomy was not recommended nevertheless underwent surgery.
When the ATA 2025 criteria were applied, 17 of the 25 patients for whom completion thyroidectomy was recommended underwent surgery, while eight did not. Furthermore, 18 of the 61 patients for whom completion thyroidectomy was not recommended nevertheless underwent surgery. Although the ATA 2025 criteria substantially reduced guideline‐based indications for completion thyroidectomy, actual surgical rates exceeded guideline projections, suggesting that factors beyond guideline criteria continue to influence operative decision‐making.
Among the 18 patients who underwent completion thyroidectomy despite not meeting ATA 2025 criteria, potentially unfavorable pathological features were more frequent than among the 43 patients in the same group who did not undergo completion (mean 1.33 vs. 1.09 features per patient; at least one potentially unfavorable feature in 89% vs. 63%). A positive surgical margin (R1) was present in 2 of the 18 patients (11%) but in none of those managed without completion (Table 4 ).
TABLE 4.
Pathological characteristics of patients not meeting ATA 2025 criteria for completion thyroidectomy, stratified by whether completion thyroidectomy was performed (N = 61).
| Pathological feature | Completion performed (n = 18) n (%) | No completion (n = 43) n (%) |
|---|---|---|
| Tumor size > 2 cm | 6 (33) | 10 (23) |
| Multifocality | 6 (33) | 11 (26) |
| Capsular invasion | 7 (41) a | 23 (53) |
| Lymphovascular invasion | 1 (6) | 0 (0) |
| Extrathyroidal extension | 0 (0) | 0 (0) |
| Central lymph node metastasis | 1 (6) | 2 (5) |
| Positive surgical margin (R1) | 2 (11) | 0 (0) |
| Aggressive PTC variant b | 1 (6) | 1 (2) |
| ≥ 1 potentially unfavorable pathological feature c | 16 (89) | 27 (63) |
Abbreviation: PTC, papillary thyroid carcinoma.
Capsular invasion was assessable in 17 of 18 patients in the completion group.
Aggressive PTC variant comprises tall cell, hobnail, and diffuse sclerosing subtypes.
Potentially unfavorable pathological features comprised tumor size > 2 cm, multifocality, capsular invasion, lymphovascular invasion, extrathyroidal extension, central lymph node metastasis, positive surgical margin (R1), and aggressive PTC variant. Owing to the limited subgroup sizes, data are presented descriptively without inferential testing.
4. Discussion
The 2015 and 2025 updates of the ATA guidelines reflect a progressive shift toward surgical de‐escalation in low‐risk differentiated thyroid cancer, with broader hemithyroidectomy eligibility and reduced completion thyroidectomy recommendations. Whether this conceptual shift translates into tangible differences in real‐world surgical decision‐making remains unclear. In the present study, we examined how the ATA 2025 criteria modify hemithyroidectomy eligibility and completion thyroidectomy recommendations compared with the 2015 version, and how these theoretical changes align with actual surgical practice in our single‐center cohort.
The 2015 ATA guidelines positioned hemithyroidectomy as an acceptable alternative to total thyroidectomy for patients with intrathyroidal, low‐risk papillary thyroid cancers measuring 1–4 cm [1, 6]. The 2025 update further advances this de‐escalation strategy by refining risk stratification, incorporating molecular parameters, and integrating dynamic risk assessment within the proposed DATA (Diagnosis–Assessment–Treatment–Assessment) framework [2, 3]. Surgical planning is therefore no longer driven solely by tumor size and static histopathology but by an individualized risk profile, with the aim of minimizing unnecessary completion thyroidectomy without compromising oncologic safety. In our cohort, application of the ATA 2025 criteria translated into a clinically meaningful expansion of hemithyroidectomy eligibility and reduction in completion thyroidectomy recommendations.
A trend toward broader hemithyroidectomy adoption following the 2015 ATA update has been consistently demonstrated in large registry and multicenter studies, with HT rates rising substantially in NSQIP, SEER, and multicenter cohorts, and without a parallel rise in completion thyroidectomy [1, 7, 15]. Because our study period began shortly after publication of the ATA 2015 guidelines, gradual rather than immediate adoption into routine practice may have contributed to the observed discrepancy between guideline‐based recommendations and actual surgical decisions. In our cohort, application of the ATA 2025 criteria significantly expanded hemithyroidectomy eligibility and reduced completion thyroidectomy recommendations, yet the actual completion rate in routine practice remained higher than these guideline‐based projections.
Although total thyroidectomy is associated with risks such as hypoparathyroidism and recurrent laryngeal nerve injury, these outcomes were not assessed in the present study and are noted only as general background; our analysis was confined to differences in surgical strategy and guideline‐driven decision‐making.
The persistent gap between guideline‐based eligibility and actual surgical practice in our cohort may be influenced by multiple factors beyond the guidelines themselves. Surgeon‐related factors, including clinical experience, individual risk tolerance, and concern about the need for reoperation, may contribute to a preference for more extensive initial resection. Patient‐related factors, such as recurrence anxiety, preferences for definitive treatment, and comorbidities, may also influence the extent of surgery. In addition, intraoperative findings and uncertainty in pathological risk assessment may lead surgeons to adopt a more cautious approach. Together, these factors likely contribute to the divergence between guideline‐based recommendations and real‐world surgical practice [16, 17, 18], reflecting the complexity of translating algorithmic frameworks into individualized clinical decisions.
Notably, the higher real‐world completion rate may, at least in part, reflect individualized risk assessment rather than solely variation from guideline‐based recommendations. Among patients not meeting ATA 2025 criteria, those who underwent completion had a greater burden of potentially unfavorable pathological features, and a positive surgical margin, a recognized trigger for surgical escalation, was present exclusively among patients who proceeded to completion. These findings may be consistent with the patient‐centered framework emphasized by the ATA 2025 update. However, because this comparison involved small subgroups (n = 18 vs. 43) and was analyzed descriptively without inferential testing, it should be regarded as exploratory and hypothesis‐generating rather than confirmatory. Practice variation cannot be excluded as an alternative explanation for some discordant completion thyroidectomies.
As hemithyroidectomy indications have broadened, the risk of requiring a second operation has become a central concern in the de‐escalation debate. Even with meticulous preoperative and intraoperative assessment, 30%–40% of patients initially considered low‐risk ultimately require completion thyroidectomy after high‐risk features are identified on final pathology [19, 20], and existing nomograms remain insufficient to reliably identify these patients preoperatively [21]. This inherent uncertainty likely underlies the residual caution observed in our cohort, where actual completion thyroidectomy rates exceeded ATA 2025 guideline‐based projections.
The predictive performance of the ATA risk classification system also remains debated. Studies have shown that microscopic features such as minimal extrathyroidal extension, multifocality, and small lymph node metastases are frequently detected but do not consistently correlate with clinically aggressive disease [5, 22]. The expansion of hemithyroidectomy eligibility observed in our cohort under the ATA 2025 criteria reflects this evolving understanding, demonstrating that reclassification of microscopic pathological features can directly influence surgical decision‐making. Incorporating thyroglobulin levels and refined lymph node assessment into risk stratification may further enhance recurrence prediction and support individualized surgical planning [21, 23].
The translation of guideline recommendations into routine surgical practice has been heterogeneous. Several studies have demonstrated that total thyroidectomy continued to predominate even after the 2015 ATA revision, with hemithyroidectomy adoption varying widely across centers and countries [24, 25, 26, 27]. Importantly, Ellsworth et al. observed that the post‐2015 increase in hemithyroidectomy was driven largely by low‐volume surgeons, who simultaneously exhibited higher complication and readmission rates compared with high‐volume counterparts [28], underscoring that guideline adoption does not necessarily equate to uniform quality of implementation. Although the ATA 2025 framework theoretically reduced the need for surgical escalation in our cohort, operative practice remained more conservative than guideline‐based projections.
Several limitations should be acknowledged when interpreting our findings. Because this was a retrospective, single‐center study conducted at a high‐volume endocrine surgery center, the findings may not be generalizable to institutions with different patient populations, lower surgical volumes, or varying levels of expertise. In addition, the relatively short follow‐up duration precludes reliable assessment of long‐term oncologic outcomes, such as recurrence or disease‐specific survival, which remain critical endpoints in differentiated thyroid cancer. Accordingly, this study's findings should be interpreted as reflecting the impact of evolving guideline criteria on surgical decision‐making rather than oncologic safety. The wide interquartile range of follow‐up reflects heterogeneous duration arising from the recency of many operations during the study period and from variable referral patterns.
Several limitations also stem from the reclassification design itself. Because a single consensus classification was retained rather than the reviewers' independent ratings, we could not report a formal inter‐rater agreement statistic (Cohen's κ); the stability of the final estimates therefore rests on consensus review rather than a quantified agreement coefficient. The reviewers were also not blinded to whether completion thyroidectomy had been performed, which may have influenced the retrospective assignment of guideline‐based recommendations and the apparent relationship between guideline classifications and real‐world practice. Accordingly, the practice‐concordance findings and the interpretation of individualized risk assessment should be considered exploratory. In addition, eligibility and completion recommendations were assigned from final histopathology, which was unavailable at the time of surgical planning. Therefore, the observed expansion in hemithyroidectomy eligibility represents a retrospective, hindsight construct rather than a factor that could have altered preoperative decisions. The cohort was also restricted to patients who underwent primary hemithyroidectomy; those triaged directly to total thyroidectomy were not included, which enriches the sample for conservative surgical management and may inflate the apparent hemithyroidectomy eligibility under both guidelines.
Molecular profiling and dynamic risk stratification were not included in the analysis. These factors are increasingly integrated into contemporary ATA‐based management frameworks and may influence surgical decision‐making. The inclusion of molecular markers and postoperative response‐to‐therapy assessment could further refine risk stratification, potentially affecting eligibility for hemithyroidectomy and completion thyroidectomy. In our cohort, molecular testing (e.g., BRAF mutation analysis) was performed in only a small subset of patients and was not routinely incorporated into clinical decision‐making, reflecting real‐world practice patterns during the study period.
The higher concordance odds ratio observed under ATA 2025 (5.08 vs. 3.00) should be interpreted with caution. Because the ATA 2025 criteria designate fewer patients as having a completion indication, this smaller group is more selected and higher‐risk, with correspondingly higher surgical uptake (68% vs. 55% under ATA 2015), whereas uptake among patients without an indication remained essentially unchanged. The increased odds ratio may therefore partly reflect this selection effect rather than improved guideline–practice alignment.
Finally, clinically relevant postoperative outcomes were not systematically recorded in this retrospective dataset. In particular, biochemical hypocalcemia was not routinely assessed following hemithyroidectomy; therefore, reliable evaluation of hypocalcemia rates was not feasible. Incidental parathyroid tissue was identified in a subset of patients, a finding associated with an increased risk of postoperative hypocalcemia; however, its clinical impact could not be reliably assessed due to the absence of standardized biochemical monitoring.
5. Conclusion
The application of the ATA 2025 criteria significantly expanded hemithyroidectomy eligibility in our cohort (from 60.5% to 81.4%) and reduced guideline‐based indications for completion thyroidectomy (from 44.2% to 29.1%). However, the actual completion thyroidectomy rate (40.7%) remained higher than the guideline‐based projections, highlighting the continued influence of postoperative risk reassessment and surgical caution in routine clinical decision‐making. Although the 2025 update clearly advances the de‐escalation paradigm, its impact in our analysis is best understood as a change in guideline‐based surgical strategy rather than in clinical outcomes, which were beyond the scope of this study.
Funding
The authors have nothing to report.
Ethics Statement
This study was performed in accordance with the principles of the Declaration of Helsinki, and it was approved by the Marmara University School of Medicine Clinical Research Ethics Committee (Number: 09.2025.25.1080). Due to the retrospective nature of the study, the requirement for informed consent was waived by the Ethics Committee.
Consent
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The initial draft was prepared in Turkish and translated into English using DeepL (http://deepl.com/en/translator). Grammarly (http://app.grammarly.com/), Trinka (trinka.ai), and ChatGPT (http://chat.openai.com/) were used to improve grammar, clarity, and readability. All content was reviewed and edited by the authors, who take full responsibility for the manuscript.
Ergenç M., Metin P., Demirbağ B., and Uğurlu M. Ü., “Hemithyroidectomy Eligibility Under ATA 2015 and 2025 Criteria: A Reclassification Cohort Study,” The Laryngoscope 136, no. 12 (2026): 5606–5614, 10.1002/lary.70843.
Part of the data from this study was presented as an oral presentation at the 24th National Surgical Congress, held April 8–12, 2026, in Antalya, Turkey.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Halagur A. S., Huynh J. D., and Megwalu U. C., “Impact of the 2015 American Thyroid Association Guidelines on Treatment of Low‐Risk Thyroid Cancer,” Laryngoscope Investigative Otolaryngology 10, no. 3 (2025): e70175, 10.1002/lio2.70175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Praw S. S., Gigliotti B. J., Tessnow A., Kang H., and Margulies D. J., “Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients With Differentiated Thyroid Cancer,” Thyroid 35, no. 11 (2025): 1214–1220, 10.1177/10507256251390877. [DOI] [PubMed] [Google Scholar]
- 3. Ringel M. D., Sosa J. A., Baloch Z., et al., “2025 American Thyroid Association Management Guidelines for Adult Patients With Differentiated Thyroid Cancer,” Thyroid 35, no. 8 (2025): 841–985, 10.1177/10507256251363120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Lohia S., Hanson M., Tuttle R. M., and Morris L. G. T., “Active Surveillance for Patients With Very Low‐Risk Thyroid Cancer,” Laryngoscope Investigative Otolaryngology 5, no. 1 (2020): 175–182, 10.1002/lio2.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Robenshtok E., Neeman B., Reches L., et al., “Adverse Histological Features of Differentiated Thyroid Cancer Are Commonly Found in Autopsy Studies: Implications for Treatment Guidelines,” Thyroid 32, no. 1 (2022): 37–45, 10.1089/thy.2021.0268. [DOI] [PubMed] [Google Scholar]
- 6. Haugen B. R., Alexander E. K., Bible K. C., et al., “2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer,” Thyroid 26, no. 1 (2016): 1–133, 10.1089/thy.2015.0020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Conroy P. C., Wilhelm A., Calthorpe L., et al., “Endocrine Surgeons Are Performing More Thyroid Lobectomies for Low‐Risk Differentiated Thyroid Cancer Since the 2015 ATA Guidelines,” Surgery 172, no. 5 (2022): 1392–1400, 10.1016/j.surg.2022.06.031. [DOI] [PubMed] [Google Scholar]
- 8. Paluskievicz C. M., Chang D. R., Blackburn K. W., et al., “Low‐Risk Papillary Thyroid Cancer: Treatment De‐Escalation and Cost Implications,” Journal of Surgical Research 275 (2022): 273–280, 10.1016/j.jss.2022.01.019. [DOI] [PubMed] [Google Scholar]
- 9. Reed R., Strumpf A., Martz T. G., et al., “2015 American Thyroid Association Guidelines and Thyroid‐Stimulating Hormone Suppression After Thyroid Lobectomy,” Head & Neck 43, no. 2 (2021): 639–644, 10.1002/hed.26524. [DOI] [PubMed] [Google Scholar]
- 10. Ahmadi S. and Alexander E. K., “Active Surveillance for Low‐Risk Differentiated Thyroid Cancer,” Endocrine Practice 29, no. 2 (2023): 148–153, 10.1016/j.eprac.2022.10.005. [DOI] [PubMed] [Google Scholar]
- 11. Baloch Z. W., Asa S. L., Barletta J. A., et al., “Overview of the 2022 WHO Classification of Thyroid Neoplasms,” Endocrine Pathology 33, no. 1 (2022): 27–63, 10.1007/s12022-022-09707-3. [DOI] [PubMed] [Google Scholar]
- 12. Papoian V., Marji F. P., Rosen J. E., Carroll N. M., and Felger E. A., “Safety of Thyroid Surgery in the Elderly: A Propensity Score Matched Cohort Study,” Journal of Surgical Research 242 (2019): 239–243, 10.1016/j.jss.2019.04.012. [DOI] [PubMed] [Google Scholar]
- 13. Lorenz K., Raffaeli M., Barczyński M., Lorente‐Poch L., and Sancho J., “Volume, Outcomes, and Quality Standards in Thyroid Surgery: An Evidence‐Based Analysis‐European Society of Endocrine Surgeons (ESES) Positional Statement,” Langenbeck's Archives of Surgery 405, no. 4 (2020): 401–425, 10.1007/s00423-020-01907-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Sanabria A., Rojas A., Arevalo J., Kowalski L. P., and Nixon I., “Microscopically Positive Surgical Margins and Local Recurrence in Thyroid Cancer. A Meta‐Analysis,” European Journal of Surgical Oncology 45, no. 8 (2019): 1310–1316, 10.1016/j.ejso.2019.02.007. [DOI] [PubMed] [Google Scholar]
- 15. Ullmann T. M., Gray K. D., Stefanova D., et al., “The 2015 American Thyroid Association Guidelines Are Associated With an Increasing Rate of Hemithyroidectomy for Thyroid Cancer,” Surgery 166, no. 3 (2019): 349–355, 10.1016/j.surg.2019.03.002. [DOI] [PubMed] [Google Scholar]
- 16. Marciniak C., Lenne X., Clément G., et al., “Partial Versus Total Thyroidectomy: What Influences Most Surgeons' Decision? Analysis of a Nationwide Cohort of 375,810 Patients Over 10 Years,” Annals of Surgery 274, no. 5 (2021): 829–835. [DOI] [PubMed] [Google Scholar]
- 17. Wei J., Thwin M., Nickel B., and Glover A., “Factors That Inform Individual Decision Making Between Active Surveillance, Hemithyroidectomy and Total Thyroidectomy for Low‐Risk Thyroid Cancer: A Scoping Review,” Thyroid 32, no. 7 (2022): 807–818, 10.1089/thy.2021.0646. [DOI] [PubMed] [Google Scholar]
- 18. Liu W., Yan X., and Cheng R., “Continuing Controversy Regarding Individualized Surgical Decision‐Making for Patients With 1‐4 Cm Low‐Risk Differentiated Thyroid Carcinoma: A Systematic Review,” European Journal of Surgical Oncology 46, no. 12 (2020): 2174–2184, 10.1016/j.ejso.2020.08.014. [DOI] [PubMed] [Google Scholar]
- 19. Craig S. J., Bysice A. M., Nakoneshny S. C., Pasieka J. L., and Chandarana S. P., “The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low‐Risk Papillary Thyroid Cancer Patients,” Thyroid 30, no. 2 (2020): 222–228, 10.1089/thy.2019.0274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Worrall B. J., Papachristos A., Aniss A., et al., “Lobectomy and Completion Thyroidectomy Rates Increase After the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines Update,” Endocrine Oncology 3, no. 1 (2023): e220095, 10.1530/eo-22-0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Wang H., Li Q., Tian T., Liu B., and Tian R., “Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer,” Journal of Clinical Endocrinology and Metabolism 110, no. 2 (2025): 534–541, 10.1210/clinem/dgae465. [DOI] [PubMed] [Google Scholar]
- 22. Tran A., Weigel R. J., and Beck A. C., “ATA Risk Stratification in Papillary Thyroid Microcarcinoma Has Low Positive Predictive Value When Identifying Recurrence,” American Journal of Surgery 229 (2024): 106–110, 10.1016/j.amjsurg.2023.11.003. [DOI] [PubMed] [Google Scholar]
- 23. de Carvalho A. Y., Kohler H. F., de Carvalho C. C. G. Y., Vartanian J. G., and Kowalski L. P., “Predictors of Recurrence After Total Thyroidectomy in 1,611 Patients With Papillary Thyroid Carcinoma: Postoperative Stimulated Serum Thyroglobulin and ATA Initial and Dynamic Risk Assessment,” Archives of Endocrinology and Metabolism 68 (2024): e220506, 10.20945/2359-4292-2022-0506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Puttergill B., Khan S., Christakis I., et al., “Thyroid Lobectomy for Low‐Risk Thyroid Cancers,” Annals of the Royal College of Surgeons of England 104, no. 2 (2022): 113–116, 10.1308/rcsann.2021.0058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Wu J., Hu X. Y., Ghaznavi S., et al., “The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting,” Thyroid 32, no. 12 (2022): 1509–1518, 10.1089/thy.2022.0055. [DOI] [PubMed] [Google Scholar]
- 26. Adhami M., Bhatt C. R., Grodski S., Serpell J., and Lee J. C., “Less Extensive Surgery for Low‐Risk Papillary Thyroid Cancers Post 2015 American Thyroid Association Guidelines in an Australian Tertiary Centre,” European Journal of Surgical Oncology 47, no. 11 (2021): 2781–2787, 10.1016/j.ejso.2021.06.018. [DOI] [PubMed] [Google Scholar]
- 27. Rathod R., Panda N. K., Bakshi J., Nayak G., and Ramavat A., “Hemithyroidectomy in Papillary Thyroid Cancers: A Prospective, Single Institutional Surgical Audit and Contemplating on the Clinical Implications of 2015 American Thyroid Association Guidelines,” Indian Journal of Otolaryngology and Head & Neck Surgery 75, no. 2 (2023): 508–516, 10.1007/s12070-022-03312-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Ellsworth B. L., Sinco B., Matusko N., et al., “Examining National Guideline Changes Association With Hemithyroidectomy Rates by Surgeon Volume,” Journal of Surgical Research 283 (2023): 858–866, 10.1016/j.jss.2022.11.037. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
